KNSA
KNSA
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
76
$176.68M
Total Volume
$176.68M
76 transactions
Net Activity
$176.68M
Net selling
Sentiment Rating
Heavy DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Patel Sanj K
COB, CEO
$95.93M total
Tessari Eben
COO
$18.26M total
Paolini John F.
CHIEF MEDICAL OFFICER
$17.89M total
Moat Ross
COO
$13.66M total
Ragosa Mark
CFO
$13.32M total
Quick Actions
KNSA has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. KNSA ranks #25 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at KNSA (KNSA) engaged in a total of 76 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 76 were sales. The total volume of insider trading reached $176.68M.
The net insider activity for KNSA shows a net selling bias of $176.68M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Patel Sanj K (COB, CEO), who traded 402.5K shares valued at $37.40M on Oct 30, 2026.
Kiniksa Pharmaceuticals, Ltd. (KNSA) stock price, news, quote and history
TD Cowen highlights catalysts for a 2027 Best Idea stock
TD Cowen Lifts Kiniksa Target to $115, Touts Wholly Owned Drug as 2027 EPS Lever
KNSA - Kiniksa Pharmaceuticals International Plc Stock Price and Quote
Kiniksa Pharmaceuticals Has Strong Growth And Little Room For Disappointment (NASDAQ:KNSA)
TD Cowen Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock
FAQs About KNSA Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for KNSA.